NCT00003417 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Corn BW, Wang M, Fox S, Michalski J, Purdy J, Simpson J, Kresl J, Curran WJ Jr, Diaz A, Mehta M, Movsas B
Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimension
Fox W, Berkey B, Michalski J, et al
: Health-related quality of life and cognitive status in patiens with glioblastoma multiforme receiving escalating doses of comformal three-dimensional radiation on RTOG 9803. [Abstract] Int J Radiat Oncol Biol Phys 63
Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP; Radiation Therapy Oncology Group Trial 98-03
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Ra
Werner-Wasik M, Seiferheld W, Michalski J, et al
: Phase I/II conformal three-dimensional radiation therapy dose escalation study in patients with supratentorial glioblastoma multiforme: report of the Radiation Therapy Oncology Group 98-03 protocol. [Abst

Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme

Clinical trial NCT00003417 - References